Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free CPHI Stock Alerts

China Pharma (CPHI) Financials

China Pharma logo
$1.23 +0.13 (+11.82%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$1.15 -0.08 (-6.18%)
As of 07/16/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for China Pharma

Annual Income Statements for China Pharma

This table shows China Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.88 -9.18 -16 -11 -21 -2.87 -3.40 -3.97 -3.08 -4.74 -3.19
Consolidated Net Income / (Loss)		 -15 -9.18 -19 -11 -21 -2.87 -3.40 -3.97 -3.08 -4.74 -3.19
Net Income / (Loss) Continuing Operations		 -1.88 -9.18 -19 -11 -21 -2.87 -3.40 -3.97 -3.08 -4.74 -3.19
Total Pre-Tax Income 		-15 -8.87 -19 -11 -21 -2.87 -3.40 -3.97 -3.08 -4.74 -3.19
Total Operating Income		 -5.79 -8.16 -19 -10 -20 -2.58 -2.86 -3.55 -2.75 -4.59 -3.24
Total Gross Profit		 1.46 3.22 2.47 1.37 1.48 1.95 0.60 -0.49 -0.28 -1.99 -0.13
Total Revenue		 20 16 13 12 11 11 9.64 8.10 7.01 4.53 4.14
Operating Revenue		 20 16 13 12 11 11 9.64 8.10 7.01 4.53 4.14
Total Cost of Revenue		 19 12 11 11 9.44 8.91 9.04 8.60 7.29 6.51 4.28
Operating Cost of Revenue		 19 12 11 10 9.44 8.91 9.29 8.60 7.29 6.51 4.28
Other Cost of Revenue		 - - - 0.60 0.00 - -0.26 - - - -0.00
Total Operating Expenses		 7.26 11 21 12 22 4.53 3.46 3.06 2.47 2.60 2.96
Selling, General & Admin Expense		 6.19 6.30 5.48 5.17 4.64 4.04 3.15 2.96 2.25 2.31 2.83
Research & Development Expense		 0.96 0.37 0.09 0.17 0.23 0.38 0.32 0.19 0.24 0.28 0.13
Total Other Income / (Expense), net		 3.97 -0.72 -0.47 -0.41 -0.29 -0.29 -0.54 -0.42 -0.33 -0.15 -0.10
Interest Expense		 -1.17 0.85 0.54 0.45 0.32 0.29 0.54 0.43 0.33 0.15 0.10
Interest & Investment Income		 1.76 0.13 0.06 0.04 0.03 0.01 0.00 0.01 0.01 0.01 0.00
Income Tax Expense		 0.06 0.31 0.12 -0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.35) ($0.21) ($0.44) ($0.25) ($0.48) ($0.07) ($0.74) ($3.78) ($0.91) ($2.71) ($0.74)
Weighted Average Basic Shares Outstanding		 43.58M 43.58M 43.58M 43.58M 43.58M 43.62M 4.61M 1.05M 3.38M 1.75M 4.29M
Diluted Earnings per Share		 ($0.35) ($0.21) ($0.44) ($0.25) ($0.48) ($0.07) - - ($0.91) ($2.71) ($0.74)
Weighted Average Diluted Shares Outstanding		 43.58M 43.58M 43.58M 43.58M 43.58M 43.62M 46.13M 8.46M 14.82M 32.62M 40.52M
Weighted Average Basic & Diluted Shares Outstanding		 43.58M 43.58M 43.58M 43.58M 43.58M 43.62M 46.13M 8.46M 14.82M 32.62M 40.52M

Quarterly Income Statements for China Pharma

This table shows China Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.78 -1.23 -0.96 -1.44 -1.12 -1.22 -0.79 -0.53 -0.65 -1.22 -1.14
Consolidated Net Income / (Loss)		 -0.78 -1.23 -0.96 -1.44 -1.12 -1.22 -0.79 -0.53 -0.65 -1.22 -1.14
Net Income / (Loss) Continuing Operations		 -0.78 -1.23 -0.96 -1.44 -1.12 -1.22 -0.79 -0.53 -0.65 -1.22 -1.14
Total Pre-Tax Income 		-0.78 -1.23 -0.96 -1.44 -1.12 -1.22 -0.79 -0.53 -0.65 -1.22 -1.14
Total Operating Income		 -0.71 -1.18 -0.92 -1.39 -1.09 -1.20 -0.76 -0.65 -0.63 -1.20 -1.12
Total Gross Profit		 -0.23 -0.08 -0.29 -1.02 -0.52 -0.16 -0.14 -0.09 -0.06 0.15 0.29
Total Revenue		 1.80 2.15 1.37 0.92 1.10 1.13 1.14 1.03 0.76 1.23 0.98
Operating Revenue		 1.80 2.15 1.37 0.92 1.10 1.13 1.14 1.03 0.76 1.23 0.98
Total Cost of Revenue		 2.04 2.22 1.66 1.94 1.62 1.30 1.27 1.11 0.82 1.07 0.70
Operating Cost of Revenue		 2.04 2.23 1.66 1.94 1.62 1.29 1.27 1.11 0.82 1.08 0.70
Total Operating Expenses		 0.48 1.11 0.63 0.38 0.57 1.03 0.62 0.41 0.57 1.35 1.40
Selling, General & Admin Expense		 0.45 0.95 0.60 0.20 0.48 1.03 0.59 0.54 0.50 1.19 1.32
Research & Development Expense		 0.05 0.15 0.03 0.16 0.09 0.00 0.03 -0.13 0.04 0.19 0.08
Other Operating Expenses / (Income)		 -0.02 - -0.00 0.01 - - -0.00 - 0.03 - -0.00
Total Other Income / (Expense), net		 -0.06 -0.05 -0.04 -0.05 -0.03 -0.03 -0.03 -0.03 -0.02 -0.02 -0.03
Interest Expense		 0.07 0.05 0.04 0.05 0.03 0.03 0.03 0.03 0.02 0.02 0.03
Interest & Investment Income		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.29) ($0.36) ($0.72) ($0.89) ($0.65) ($0.70) ($0.24) ($0.16) ($0.17) ($0.28) ($0.04)
Weighted Average Basic Shares Outstanding		 2.64M 3.38M 1.33M 1.61M 1.73M 1.75M 3.26M 3.26M 3.87M 4.29M 25.60M
Diluted Earnings per Share		 ($0.29) ($0.36) ($0.72) ($0.89) ($0.65) ($0.70) ($0.24) ($0.16) ($0.17) ($0.28) ($0.04)
Weighted Average Diluted Shares Outstanding		 32.95M 14.82M 15.87M 17.16M 19.25M 0.00 3.26M 3.26M 5.02M 0.00 40.52M
Weighted Average Basic & Diluted Shares Outstanding		 32.95M 14.82M 15.87M 17.16M 19.25M 0.00 3.26M 3.26M 5.02M 0.00 40.52M

Annual Cash Flow Statements for China Pharma

This table details how cash moves in and out of China Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.95 -3.58 -0.64 -0.28 -1.28 -0.23 3.90 -2.83 -0.61 -0.80 -0.28
Net Cash From Operating Activities		 3.35 2.90 0.84 1.88 0.61 -0.04 -0.25 -0.41 -0.70 -0.41 0.15
Net Cash From Continuing Operating Activities		 -7.60 2.90 0.84 1.88 0.61 -0.04 -0.25 -0.41 -0.70 -0.47 0.15
Net Income / (Loss) Continuing Operations		 -15 -9.18 -19 -11 -21 -2.87 -3.40 -3.97 -3.08 -4.74 -3.19
Consolidated Net Income / (Loss)		 -15 -9.18 -19 -11 -21 -2.87 -3.40 -3.97 -3.08 -4.74 -3.19
Depreciation Expense		 3.60 3.08 3.29 3.26 2.93 2.68 3.09 2.70 2.75 2.62 1.58
Non-Cash Adjustments To Reconcile Net Income		 12 5.43 17 7.59 17 0.28 -0.24 -0.48 0.02 0.44 -13
Changes in Operating Assets and Liabilities, net		 2.96 3.57 -0.48 1.78 1.11 -0.14 0.05 1.34 -0.40 1.21 15
Net Cash From Investing Activities		 -1.90 -0.19 -0.14 -0.05 -0.14 -0.87 -0.44 -0.40 -0.01 -0.29 -0.14
Net Cash From Continuing Investing Activities		 1.90 -0.19 -0.14 -0.05 -0.14 -0.87 -0.44 -0.40 -0.01 -0.29 -0.14
Purchase of Property, Plant & Equipment		 -0.69 -0.19 -0.14 -0.05 -0.14 -0.87 -0.44 -0.40 -0.01 -0.04 -0.06
Acquisitions		 -1.63 - - - - - - - 0.00 -0.25 -0.08
Net Cash From Financing Activities		 0.00 -6.02 -1.48 -1.98 -1.73 0.62 4.60 -1.77 0.07 -0.03 -0.29
Net Cash From Continuing Financing Activities		 0.00 -6.02 -1.48 -1.98 -1.73 0.62 4.60 -1.77 0.07 -0.03 -0.29
Repayment of Debt		 0.00 -6.02 -1.48 -2.26 -2.42 -2.44 -2.89 -2.36 -1.49 -0.49 -1.26
Issuance of Debt		 - - 0.00 0.29 0.69 3.06 2.49 0.59 1.56 0.52 0.96
Cash Interest Paid		 1.15 0.84 0.53 0.59 0.30 0.24 0.22 0.14 0.09 0.09 0.07
Cash Income Taxes Paid		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for China Pharma

This table details how cash moves in and out of China Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.47 0.05 -0.58 -0.09 -0.03 -0.09 -0.21 0.21 -0.36 0.08 -0.18
Net Cash From Operating Activities		 1.01 -0.02 -0.59 -0.07 -0.05 0.30 -0.07 0.29 -0.24 0.15 -0.06
Net Cash From Continuing Operating Activities		 1.01 -0.02 -0.59 -0.07 -0.05 0.30 -0.07 0.29 -0.24 0.15 -0.06
Net Income / (Loss) Continuing Operations		 -0.78 -1.23 -0.96 -1.44 -1.12 -1.22 -0.79 -0.53 -0.65 -1.22 -1.14
Consolidated Net Income / (Loss)		 -0.78 -1.23 -0.96 -1.44 -1.12 -1.22 -0.79 -0.53 -0.65 -1.22 -1.14
Depreciation Expense		 0.68 0.70 0.73 0.74 0.70 0.51 0.33 0.32 0.36 0.57 0.98
Non-Cash Adjustments To Reconcile Net Income		 0.15 0.00 0.12 0.32 0.04 -0.02 0.22 0.14 0.18 -14 0.00
Changes in Operating Assets and Liabilities, net		 0.96 0.51 -0.49 0.31 0.33 1.04 0.16 0.36 -0.12 14 0.11
Net Cash From Investing Activities		 -0.07 -0.00 0.00 -0.03 0.01 -0.27 -0.06 -0.01 -0.04 -0.01 0.00
Net Cash From Continuing Investing Activities		 -0.07 -0.00 0.00 -0.03 0.01 -0.27 -0.06 -0.01 -0.04 -0.01 0.00
Purchase of Property, Plant & Equipment		 -0.07 -0.00 0.00 -0.03 0.01 -0.02 -0.06 0.00 -0.00 -0.00 0.00
Net Cash From Financing Activities		 -0.48 0.03 0.01 0.01 0.01 -0.05 -0.08 -0.03 -0.12 -0.07 -0.08
Net Cash From Continuing Financing Activities		 -0.48 0.03 0.01 0.01 0.01 -0.05 -0.08 -0.03 -0.12 -0.07 -0.08
Repayment of Debt		 -0.46 -1.03 0.00 -0.49 - -0.06 -0.08 -1.02 0.62 -0.78 -0.08
Cash Interest Paid		 0.15 -0.10 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02

Annual Balance Sheets for China Pharma

This table presents China Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 97 79 60 45 22 21 23 18 16 15 31
Total Current Assets		 24 18 12 8.75 5.58 5.32 9.09 5.96 6.00 3.27 2.35
Cash & Equivalents		 6.25 2.67 2.03 1.19 1.07 0.96 4.86 2.03 1.42 0.63 0.35
Accounts Receivable		 5.46 4.22 2.46 1.09 0.68 0.53 0.74 0.45 0.66 0.26 0.29
Inventories, net		 9.66 9.31 6.87 5.06 3.59 3.71 3.34 2.95 3.73 2.27 1.62
Prepaid Expenses		 0.34 0.23 0.19 0.12 0.08 0.07 0.06 0.08 0.11 0.08 0.08
Other Current Assets		 2.53 0.00 0.04 0.02 0.05 0.06 0.09 0.46 0.07 0.03 0.01
Plant, Property, & Equipment, net		 29 25 24 19 16 16 13 9.97 7.10 4.88 4.39
Total Noncurrent Assets		 43 36 24 17 0.34 0.23 0.28 1.85 3.37 6.73 24
Intangible Assets		 43 36 24 17 0.21 0.18 0.15 1.81 3.26 6.70 24
Other Noncurrent Operating Assets		 - - - 0.00 0.14 0.05 0.13 0.04 0.12 0.04 0.18
Total Liabilities & Shareholders' Equity		 97 79 60 45 22 21 23 18 16 15 31
Total Liabilities		 24 20 17 15 13 13 17 13 9.01 7.14 8.26
Total Current Liabilities		 22 10 9.23 10 10 11 11 13 6.82 5.02 7.40
Short-Term Debt		 4.62 - - - 0.00 2.04 4.33 6.24 3.10 2.16 3.41
Accounts Payable		 5.89 5.56 5.35 5.76 4.93 3.98 2.81 3.06 3.25 2.41 3.45
Accrued Expenses		 0.14 0.14 0.28 0.31 0.19 0.18 0.30 0.40 0.30 0.25 0.35
Current Deferred Revenue		 0.60 0.81 0.58 0.53 0.51 0.72 - 0.52 0.09 0.16 0.11
Other Current Liabilities		 11 3.88 3.02 3.46 4.42 4.49 3.08 2.52 0.08 0.04 0.07
Total Noncurrent Liabilities		 1.84 9.21 7.65 5.13 2.95 1.71 6.12 0.75 2.19 2.12 0.86
Noncurrent Deferred & Payable Income Tax Liabilities		 0.30 0.57 0.74 0.76 0.75 0.81 0.82 0.75 0.74 0.73 0.75
Other Noncurrent Operating Liabilities		 - 8.64 6.92 4.36 2.20 0.00 0.04 0.00 0.04 0.00 0.11
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 73 59 43 30 9.24 8.00 6.02 4.29 7.45 7.75 23
Total Preferred & Common Equity		 73 59 43 30 9.24 8.00 6.02 4.29 7.45 7.75 23
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 73 59 43 30 9.24 8.00 6.02 4.29 7.45 7.75 23
Common Stock		 24 24 24 24 24 24 26 29 35 41 59
Retained Earnings		 34 25 5.48 -5.27 -26 -29 -32 -36 -39 -44 -47
Accumulated Other Comprehensive Income / (Loss)		 - 11 14 12 12 12 13 12 11 11 12
Other Equity Adjustments		 15 - - - - - - - 0.00 -0.18 -0.18

Quarterly Balance Sheets for China Pharma

This table presents China Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 15 16 14 13 14 14 16 45
Total Current Assets		 5.81 5.12 3.97 3.74 2.85 2.70 2.33 2.00
Cash & Equivalents		 1.37 0.84 0.74 0.72 0.41 0.63 0.27 0.17
Accounts Receivable		 0.40 0.39 0.28 0.38 0.37 0.32 0.29 0.26
Inventories, net		 3.77 3.68 2.82 2.50 1.98 1.68 1.65 1.50
Prepaid Expenses		 0.27 0.20 0.12 0.11 0.08 0.07 0.08 0.07
Other Current Assets		 0.00 0.00 0.02 0.03 0.01 0.00 0.05 0.00
Plant, Property, & Equipment, net		 7.77 6.45 5.82 5.31 4.78 4.63 4.50 4.30
Total Noncurrent Assets		 1.78 4.62 4.47 4.42 6.59 6.44 8.97 39
Intangible Assets		 1.64 4.52 4.39 4.36 6.57 6.44 8.78 39
Other Noncurrent Operating Assets		 0.13 0.10 0.08 0.06 0.02 0.00 0.20 0.16
Total Liabilities & Shareholders' Equity		 15 16 14 13 14 14 16 45
Total Liabilities		 9.24 7.90 6.85 6.94 7.25 7.30 7.49 8.12
Total Current Liabilities		 7.06 5.73 4.71 4.76 5.12 5.25 6.62 7.27
Short-Term Debt		 2.76 2.66 2.58 2.52 2.09 2.11 3.37 3.39
Accounts Payable		 2.82 2.77 1.75 2.07 2.70 2.88 2.89 3.43
Accrued Expenses		 0.12 0.11 0.21 0.08 0.20 0.19 0.17 0.31
Current Deferred Revenue		 0.17 0.11 0.10 0.02 0.11 0.08 0.12 0.06
Other Current Liabilities		 1.19 0.08 0.08 0.06 0.02 0.00 0.07 0.07
Total Noncurrent Liabilities		 2.18 2.17 2.14 2.18 2.13 2.05 0.87 0.85
Noncurrent Deferred & Payable Income Tax Liabilities		 0.73 0.74 0.74 0.75 0.73 0.73 0.74 0.76
Other Noncurrent Operating Liabilities		 0.06 0.02 0.00 0.00 - - 0.13 0.09
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.11 8.29 7.41 6.53 6.97 6.46 8.31 37
Total Preferred & Common Equity		 6.11 8.29 7.41 6.53 6.97 6.46 8.31 37
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 6.11 8.29 7.41 6.53 6.97 6.46 8.31 37
Common Stock		 33 37 38 38 41 41 43 74
Retained Earnings		 -38 -40 -42 -43 -45 -45 -46 -48
Accumulated Other Comprehensive Income / (Loss)		 11 11 11 12 11 11 11 12
Other Equity Adjustments		 - - - - -0.18 -0.18 -0.18 -0.18

Annual Metrics And Ratios for China Pharma

This table displays calculated financial ratios and metrics derived from China Pharma's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 43,579,557.00 43,579,557.00 43,579,557.00 43,579,557.00 43,579,557.00 43,579,557.00 47,339,557.00 51,642,530.00 32,951,673.00 19,253,363.00 5,022,002.00
DEI Adjusted Shares Outstanding		 87,159.00 87,159.00 87,159.00 87,159.00 87,159.00 87,159.00 94,679.00 103,285.00 659,033.00 1,925,336.00 5,022,002.00
DEI Earnings Per Adjusted Shares Outstanding		 -21.60 -105.35 -181.71 -123.34 -237.52 -32.89 -35.91 -38.46 -4.67 -2.46 -0.63
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -8.05% -23.49% -15.15% -6.67% -11.41% -0.53% -11.27% -15.95% -13.48% -35.41% -8.49%
EBITDA Growth		 96.89% -341.78% -203.08% 53.29% -143.15% 100.58% 371.76% -277.76% 100.22% -104,402.73% 13.18%
EBIT Growth		 87.75% -71.77% -129.05% 44.07% -95.34% 87.37% -10.95% -24.07% 22.46% -66.76% 29.41%
NOPAT Growth		 85.05% -40.78% -129.05% 44.07% -95.34% 87.37% -10.95% -24.07% 22.46% -66.76% 29.41%
Net Income Growth		 61.05% 40.39% -109.94% 44.23% -92.57% 86.15% -18.58% -16.87% 22.50% -53.84% 32.70%
EPS Growth		 61.54% 40.00% -109.52% 43.18% -92.00% 85.42% 0.00% 0.00% 0.00% -53.84% 72.69%
Operating Cash Flow Growth		 -45.55% -13.56% -70.95% 123.74% -67.68% -106.95% -491.19% -63.92% -70.84% 41.97% 136.51%
Free Cash Flow Firm Growth		 -27.74% -30.79% -85.06% 202.20% 2.28% -169.29% 26.48% 91.00% -1,505.26% 15.98% -421.37%
Invested Capital Growth		 -22.40% -23.98% -26.88% -31.22% -70.97% 24.05% 7.49% -20.83% 24.07% 1.19% 141.80%
Revenue Q/Q Growth		 6.11% 5.12% -9.67% -4.68% -1.75% -1.07% -0.43% 0.39% -9.91% -18.32% 2.27%
EBITDA Q/Q Growth		 93.43% 39.13% -201.07% 45.89% -180.93% 100.58% 303.01% -230.35% 104.69% -11.71% 6.78%
EBIT Q/Q Growth		 77.43% 30.61% -131.93% 37.17% -120.79% 87.21% 13.67% -17.18% -0.57% -0.25% -0.13%
NOPAT Q/Q Growth		 72.46% 30.61% -131.93% 37.17% -120.79% 87.21% 13.67% -17.18% -0.57% -0.25% -0.13%
Net Income Q/Q Growth		 30.61% 56.59% -117.18% 36.71% -116.80% 85.95% 6.29% -7.68% 1.03% 0.16% 0.07%
EPS Q/Q Growth		 30.00% 58.00% -131.58% 35.90% -108.70% 85.42% 0.00% 0.00% 1.03% 0.16% 9.76%
Operating Cash Flow Q/Q Growth		 -20.40% -29.71% -38.97% -3.21% -59.58% 89.41% -188.24% 65.65% -654.22% 44.16% -36.84%
Free Cash Flow Firm Q/Q Growth		 -26.76% -31.08% -48.29% -28.63% 85.39% -317.54% 0.65% -197.54% -62.08% 18.07% -343.93%
Invested Capital Q/Q Growth		 -18.23% -13.20% -26.03% -21.84% -69.15% -2.82% 0.08% 1.75% 18.63% 9.35% 126.07%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 7.20% 20.67% 18.68% 11.11% 13.57% 17.97% 6.27% -6.09% -4.01% -43.84% -3.18%
EBITDA Margin		 -5.65% -32.61% -116.47% -58.30% -160.01% 0.93% 4.95% -10.47% 0.03% -42.21% -40.05%
Operating Margin		 -28.46% -52.38% -141.38% -84.73% -186.82% -23.73% -29.67% -43.79% -39.25% -101.32% -78.16%
EBIT Margin		 -23.33% -52.38% -141.38% -84.73% -186.82% -23.73% -29.67% -43.79% -39.25% -101.32% -78.16%
Profit (Net Income) Margin		 -75.70% -58.97% -145.91% -87.18% -189.51% -26.38% -35.26% -49.02% -43.91% -104.58% -76.91%
Tax Burden Percent		 100.39% 103.47% 100.64% 98.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 323.20% 108.82% 102.54% 103.95% 101.44% 111.19% 118.84% 111.94% 111.88% 103.21% 98.41%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -4.88% -8.94% -27.39% -21.49% -79.83% -20.01% -19.32% -25.83% -20.23% -30.28% -12.43%
ROIC Less NNEP Spread (ROIC-NNEP)		 -3,362.33% 171.95% 163.58% 110.69% 272.21% -285.49% -61.00% -59.16% -51.79% -80.93% -43.15%
Return on Net Nonoperating Assets (RNNOA)		 -13.75% -5.02% -10.42% -7.86% -25.16% -13.25% -29.17% -51.26% -32.20% -32.03% -8.48%
Return on Equity (ROE)		 -18.63% -13.96% -37.81% -29.34% -104.99% -33.25% -48.49% -77.08% -52.43% -62.31% -20.91%
Cash Return on Invested Capital (CROIC)		 20.34% 18.31% 3.66% 15.51% 30.18% -41.48% -26.54% -2.57% -41.71% -31.46% -95.40%
Operating Return on Assets (OROA)		 -4.36% -9.32% -26.98% -19.84% -60.37% -11.89% -13.07% -17.55% -16.07% -29.27% -14.12%
Return on Assets (ROA)		 -14.16% -10.49% -27.84% -20.41% -61.24% -13.23% -15.53% -19.65% -17.98% -30.21% -13.89%
Return on Common Equity (ROCE)		 -18.63% -13.96% -37.81% -29.34% -104.99% -33.25% -48.49% -77.08% -52.43% -62.31% -20.91%
Return on Equity Simple (ROE_SIMPLE)		 -21.21% -15.59% -44.76% -35.60% -224.11% -35.81% -56.49% -92.61% -41.30% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.06 -5.71 -13 -7.31 -14 -1.80 -2.00 -2.48 -1.93 -3.21 -2.27
NOPAT Margin		 -19.93% -36.66% -98.97% -59.31% -130.77% -16.61% -20.77% -30.65% -27.47% -70.93% -54.71%
Net Nonoperating Expense Percent (NNEP)		 3,357.45% -180.89% -190.97% -132.18% -352.03% 265.48% 41.68% 33.34% 31.56% 50.66% 30.71%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -16.09% -28.43% -8.67%
Cost of Revenue to Revenue		 92.80% 79.33% 81.32% 88.89% 86.46% 82.03% 93.73% 106.09% 104.01% 143.84% 103.16%
SG&A Expenses to Revenue		 30.42% 40.48% 41.48% 41.90% 42.50% 37.16% 32.63% 36.56% 32.04% 51.08% 68.22%
R&D to Revenue		 4.73% 2.35% 0.68% 1.40% 2.10% 3.48% 3.31% 2.29% 3.42% 6.27% 3.12%
Operating Expenses to Revenue		 35.66% 73.05% 160.07% 95.84% 200.36% 41.70% 35.94% 37.70% 35.24% 57.48% 71.34%
Earnings before Interest and Taxes (EBIT)		 -4.75 -8.16 -19 -10 -20 -2.58 -2.86 -3.55 -2.75 -4.59 -3.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.15 -5.08 -15 -7.19 -17 0.10 0.48 -0.85 0.00 -1.91 -1.66
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.09 0.19 0.18 0.37 1.12 2.43 3.80 1.15 0.53 0.58 0.27
Price to Tangible Book Value (P/TBV)		 0.23 0.50 0.40 0.87 1.14 2.48 3.89 2.00 0.95 4.25 0.00
Price to Revenue (P/Rev)		 0.34 0.73 0.58 0.91 0.94 1.79 2.37 0.61 0.57 0.99 1.47
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.09 0.14 0.12 0.32 1.13 2.14 2.57 1.08 0.67 0.69 0.35
Enterprise Value to Revenue (EV/Rev)		 0.33 0.49 0.37 0.71 0.84 1.97 2.86 1.13 1.01 1.63 2.21
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 211.64 57.75 0.00 3,862.35 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 2.02 2.62 5.84 4.65 15.02 0.00 0.00 0.00 0.00 0.00 61.67
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.40 0.65 2.81 1.66 1.69 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.08 0.00 0.00 0.00 0.00 0.37 1.59 1.45 0.61 0.46 0.15
Long-Term Debt to Equity		 0.02 0.00 0.00 0.00 0.00 0.11 0.87 0.00 0.19 0.18 0.00
Financial Leverage		 0.00 -0.03 -0.06 -0.07 -0.09 0.05 0.48 0.87 0.62 0.40 0.20
Leverage Ratio		 1.32 1.33 1.36 1.44 1.71 2.51 3.12 3.92 2.92 2.06 1.51
Compound Leverage Factor		 4.25 1.45 1.39 1.49 1.74 2.80 3.71 4.39 3.26 2.13 1.48
Debt to Total Capital		 7.82% 0.00% 0.00% 0.00% 0.00% 26.88% 61.42% 59.26% 37.73% 31.43% 13.05%
Short-Term Debt to Total Capital		 5.87% 0.00% 0.00% 0.00% 0.00% 18.62% 27.76% 59.26% 25.93% 19.12% 13.05%
Long-Term Debt to Total Capital		 1.96% 0.00% 0.00% 0.00% 0.00% 8.26% 33.66% 0.00% 11.79% 12.31% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 92.18% 100.00% 100.00% 100.00% 100.00% 73.12% 38.58% 40.74% 62.27% 68.57% 86.95%
Debt to EBITDA		 -5.36 0.00 0.00 0.00 0.00 29.08 20.07 -7.36 2,463.93 -1.86 -2.06
Net Debt to EBITDA		 0.07 0.00 0.00 0.00 0.00 19.62 9.89 -4.96 1,687.15 -1.53 -1.85
Long-Term Debt to EBITDA		 -1.34 0.00 0.00 0.00 0.00 8.94 11.00 0.00 770.26 -0.73 0.00
Debt to NOPAT		 -1.52 0.00 0.00 0.00 0.00 -1.63 -4.78 -2.51 -2.34 -1.11 -1.51
Net Debt to NOPAT		 0.02 0.00 0.00 0.00 0.00 -1.10 -2.36 -1.70 -1.61 -0.91 -1.35
Long-Term Debt to NOPAT		 -0.38 0.00 0.00 0.00 0.00 -0.50 -2.62 0.00 -0.73 -0.43 0.00
Altman Z-Score		 0.74 0.75 -0.35 -0.24 -3.94 -1.26 -1.23 -3.29 -3.26 -4.62 -2.10
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.10 1.69 1.33 0.87 0.56 0.47 0.86 0.47 0.88 0.65 0.32
Quick Ratio		 0.53 0.66 0.49 0.23 0.17 0.13 0.53 0.19 0.31 0.18 0.09
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 17 12 1.75 5.28 5.40 -3.74 -2.75 -0.25 -3.97 -3.34 -17
Operating Cash Flow to CapEx		 488.84% 1,497.23% 616.37% 3,679.97% 447.28% -4.87% -57.03% -101.89% -6,075.25% -1,057.15% 249.92%
Free Cash Flow to Firm to Interest Expense		 0.00 13.76 3.24 11.70 16.79 -12.72 -5.08 -0.57 -11.91 -21.65 -170.54
Operating Cash Flow to Interest Expense		 0.00 3.41 1.56 4.17 1.89 -0.14 -0.46 -0.94 -2.10 -2.63 1.45
Operating Cash Flow Less CapEx to Interest Expense		 0.00 3.18 1.31 4.06 1.47 -3.09 -1.27 -1.87 -2.13 -2.88 0.87
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.19 0.18 0.19 0.23 0.32 0.50 0.44 0.40 0.41 0.29 0.18
Accounts Receivable Turnover		 2.08 3.21 3.96 6.96 12.35 17.94 15.14 13.57 12.60 9.79 14.99
Inventory Turnover		 1.51 1.30 1.33 1.84 2.19 2.44 2.57 2.74 2.18 2.17 2.20
Fixed Asset Turnover		 0.64 0.57 0.54 0.58 0.61 0.68 0.67 0.70 0.82 0.76 0.89
Accounts Payable Turnover		 3.37 2.16 1.97 1.97 1.77 2.00 2.66 2.93 2.31 2.30 1.46
Days Sales Outstanding (DSO)		 175.68 113.56 92.27 52.44 29.55 20.35 24.11 26.90 28.97 37.27 24.36
Days Inventory Outstanding (DIO)		 241.42 280.39 274.90 198.54 167.02 149.34 142.26 133.46 167.18 168.05 165.95
Days Payable Outstanding (DPO)		 108.19 169.21 185.45 185.06 206.49 182.42 137.19 124.55 157.82 158.48 250.25
Cash Conversion Cycle (CCC)		 308.91 224.75 181.72 65.92 -9.91 -12.73 29.18 35.81 38.33 46.83 -59.94
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 73 55 40 28 8.05 9.99 11 8.50 11 11 26
Invested Capital Turnover		 0.25 0.24 0.28 0.36 0.61 1.20 0.93 0.84 0.74 0.43 0.23
Increase / (Decrease) in Invested Capital		 -21 -17 -15 -13 -20 1.94 0.75 -2.24 2.05 0.13 15
Enterprise Value (EV)		 6.75 7.58 4.91 8.76 9.13 21 28 9.16 7.08 7.40 9.14
Market Capitalization		 6.84 11 7.65 11 10 19 23 4.95 3.99 4.48 6.08
Book Value per Share		 $1.67 $1.35 $0.99 $0.69 $0.21 $0.18 $0.13 $0.08 $0.23 $0.40 $4.53
Tangible Book Value per Share		 $0.68 $0.52 $0.43 $0.30 $0.21 $0.18 $0.12 $0.05 $0.13 $0.05 ($0.27)
Total Capital		 79 59 43 30 9.24 11 16 11 12 11 26
Total Debt		 6.16 0.00 0.00 0.00 0.00 2.94 9.58 6.24 4.52 3.55 3.41
Total Long-Term Debt		 1.54 0.00 0.00 0.00 0.00 0.90 5.25 0.00 1.41 1.39 0.00
Net Debt		 -0.09 -3.75 -2.74 -2.46 -1.18 1.98 4.72 4.21 3.09 2.92 3.07
Capital Expenditures (CapEx)		 0.69 0.19 0.14 0.05 0.14 0.87 0.44 0.40 0.01 0.04 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.59 3.37 0.32 -3.77 -5.65 -5.00 -1.95 -2.56 0.86 -0.21 -1.99
Debt-free Net Working Capital (DFNWC)		 6.84 7.12 3.06 -1.30 -4.47 -4.04 2.91 -0.53 2.28 0.41 -1.64
Net Working Capital (NWC)		 2.21 7.12 3.06 -1.30 -4.47 -6.08 -1.42 -6.77 -0.82 -1.75 -5.05
Net Nonoperating Expense (NNE)		 11 3.47 6.20 3.44 6.42 1.06 1.40 1.49 1.15 1.52 0.92
Net Nonoperating Obligations (NNO)		 -0.09 -3.75 -2.74 -2.46 -1.18 1.98 4.72 4.21 3.09 2.92 3.07
Total Depreciation and Amortization (D&A)		 3.60 3.08 3.29 3.26 2.93 2.68 3.34 2.70 2.75 2.68 1.58
Debt-free, Cash-free Net Working Capital to Revenue		 2.88% 21.63% 2.44% -30.53% -51.73% -46.02% -20.22% -31.64% 12.22% -4.71% -47.94%
Debt-free Net Working Capital to Revenue		 33.59% 45.74% 23.18% -10.58% -40.89% -37.21% 30.17% -6.59% 32.53% 9.13% -39.61%
Net Working Capital to Revenue		 10.88% 45.74% 23.18% -10.58% -40.89% -55.97% -14.73% -83.60% -11.75% -38.57% -121.95%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($17.50) ($10.50) ($22.00) ($12.50) ($24.00) ($3.50) ($3.50) ($3.80) ($0.91) ($2.70) ($0.74)
Adjusted Weighted Average Basic Shares Outstanding		 871.59K 871.59K 871.59K 871.59K 871.59K 911.59K 946.79K 1.05M 3.38M 1.75M 4.29M
Adjusted Diluted Earnings per Share		 ($17.50) ($10.50) ($22.00) ($12.50) ($24.00) ($3.50) ($3.50) $0.00 $0.00 ($2.70) ($0.74)
Adjusted Weighted Average Diluted Shares Outstanding		 871.59K 871.59K 871.59K 871.59K 871.59K 911.59K 946.79K 1.69M 14.82M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($10.50) ($22.00) ($12.50) ($24.00) ($3.50) ($3.50) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 871.59K 871.59K 871.59K 871.59K 871.59K 872.47K 922.59K 1.69M 14.82M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -3.98 -2.94 -3.15 -2.78 -2.37 -1.80 -2.00 -2.48 -1.93 -3.21 -2.27
Normalized NOPAT Margin		 -19.57% -18.85% -23.82% -22.53% -21.74% -16.61% -20.77% -30.65% -27.47% -70.93% -54.71%
Pre Tax Income Margin		 -75.40% -57.00% -144.98% -88.07% -189.51% -26.38% -35.26% -49.02% -43.91% -104.58% -76.91%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -9.60 -34.64 -23.15 -63.43 -8.77 -5.28 -8.17 -8.25 -29.77 -31.74
NOPAT to Interest Expense		 0.00 -6.72 -24.24 -16.21 -44.40 -6.14 -3.69 -5.72 -5.77 -20.84 -22.22
EBIT Less CapEx to Interest Expense		 0.00 -9.83 -34.89 -23.27 -63.86 -11.71 -6.09 -9.09 -8.28 -30.02 -32.33
NOPAT Less CapEx to Interest Expense		 0.00 -6.95 -24.50 -16.32 -44.83 -9.08 -4.50 -6.64 -5.81 -21.09 -22.80
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for China Pharma

This table displays calculated financial ratios and metrics derived from China Pharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 11,432,801.00 32,951,673.00 32,951,673.00 15,870,070.00 17,162,771.00 19,253,363.00 19,253,363.00 19,253,363.00 19,253,363.00 5,022,002.00 5,022,002.00
DEI Adjusted Shares Outstanding		 228,656.00 659,033.00 659,033.00 1,587,007.00 1,716,277.00 1,925,336.00 1,925,336.00 1,925,336.00 1,925,336.00 5,022,002.00 5,022,002.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.40 -1.87 -1.45 -0.91 -0.65 -0.64 -0.41 -0.27 -0.34 -0.24 -0.23
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -8.26% -26.41% -30.12% -15.75% -39.00% -47.25% -17.05% 10.90% -31.26% 8.11% -13.44%
EBITDA Growth		 -25.21% 7.73% -164.54% -373.45% -1,175.34% -41.01% -135.55% 49.21% 29.93% 8.97% 68.16%
EBIT Growth		 -3.61% -1.32% -130.47% -204.95% -52.09% -0.97% 17.19% 53.14% 42.12% -0.35% -47.28%
NOPAT Growth		 -3.61% -1.32% -130.47% -204.95% -52.09% -0.97% 17.19% 53.14% 42.12% -0.35% -47.28%
Net Income Growth		 1.67% 2.53% -100.83% -142.51% -43.76% 0.63% 17.82% 63.26% 41.72% 0.19% -45.52%
EPS Growth		 0.00% 2.53% 0.00% 0.00% -43.76% 0.63% 17.82% 82.02% 73.85% 60.00% 83.33%
Operating Cash Flow Growth		 359.69% -103.82% 60.14% 66.40% -104.66% 1,438.41% 87.41% 500.24% -404.74% -49.13% 24.95%
Free Cash Flow Firm Growth		 -154.71% -302.70% -361.46% -470.31% -57.42% 66.52% 137.15% 131.12% -28.60% -1,559.29% -3,416.92%
Invested Capital Growth		 6.41% 24.07% 19.44% 23.27% 9.78% 1.19% -12.73% -13.01% 16.96% 141.80% 300.75%
Revenue Q/Q Growth		 64.27% 19.20% -36.28% -32.48% 18.94% 3.08% 0.20% -9.73% -26.28% 62.12% -19.78%
EBITDA Q/Q Growth		 -112.76% -1,504.89% 62.70% -257.89% 40.47% -77.44% 37.69% 22.84% 17.86% -130.51% 78.21%
EBIT Q/Q Growth		 -56.37% -66.00% 22.66% -51.90% 22.01% -10.21% 36.57% 14.04% 3.68% -91.07% 6.91%
NOPAT Q/Q Growth		 -56.37% -66.00% 22.66% -51.90% 22.01% -10.21% 36.57% 14.04% 3.68% -91.07% 6.91%
Net Income Q/Q Growth		 -31.12% -58.46% 22.42% -50.45% 22.27% -9.53% 35.84% 32.74% -23.30% -87.59% 6.46%
EPS Q/Q Growth		 0.00% -58.46% 22.42% -50.45% 22.27% -9.53% 35.84% 33.33% -6.25% -64.71% 85.71%
Operating Cash Flow Q/Q Growth		 565.40% -102.22% -2,521.32% 87.57% 35.44% 736.34% -124.66% 603.41% -181.42% 164.13% -136.38%
Free Cash Flow Firm Q/Q Growth		 -228.43% -177.82% 12.54% -18.67% 45.40% 40.91% 197.04% -0.60% -325.62% -662.43% -93.99%
Invested Capital Q/Q Growth		 2.93% 18.63% 9.12% -7.48% -8.34% 9.35% -5.89% -7.78% 23.24% 126.07% 55.97%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -12.93% -3.49% -21.17% -109.78% -47.23% -14.16% -11.97% -8.68% -7.89% 12.46% 29.03%
EBITDA Margin		 -1.69% -22.73% -13.30% -70.52% -35.30% -60.76% -37.78% -32.29% -35.98% -51.16% -13.90%
Operating Margin		 -39.57% -55.10% -66.87% -150.44% -98.65% -105.47% -66.76% -63.57% -83.06% -97.90% -113.60%
EBIT Margin		 -39.57% -55.10% -66.87% -150.44% -98.65% -105.47% -66.76% -63.57% -83.06% -97.90% -113.60%
Profit (Net Income) Margin		 -43.12% -57.32% -69.78% -155.48% -101.61% -107.98% -69.14% -51.51% -86.15% -99.69% -116.23%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 108.98% 104.03% 104.35% 103.35% 103.01% 102.37% 103.55% 81.02% 103.72% 101.83% 102.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -25.00% -28.39% -28.43% -68.23% -41.06% -31.51% -18.63% -19.65% -22.25% -15.57% -12.62%
ROIC Less NNEP Spread (ROIC-NNEP)		 -31.70% -39.43% -36.12% -80.57% -52.98% -44.38% -26.72% -22.03% -28.94% -28.32% -24.08%
Return on Net Nonoperating Assets (RNNOA)		 -29.41% -24.52% -22.80% -51.55% -25.20% -17.57% -11.01% -9.59% -12.35% -5.57% -3.45%
Return on Equity (ROE)		 -54.41% -52.92% -51.23% -119.78% -66.25% -49.08% -29.64% -29.25% -34.60% -21.14% -16.07%
Cash Return on Invested Capital (CROIC)		 -28.42% -41.71% -39.37% -51.37% -43.68% -31.46% -15.19% -12.05% -37.02% -95.40% -130.13%
Operating Return on Assets (OROA)		 -19.52% -22.56% -25.60% -62.74% -37.96% -30.47% -18.86% -19.94% -23.00% -17.68% -15.28%
Return on Assets (ROA)		 -21.27% -23.47% -26.71% -64.84% -39.10% -31.19% -19.53% -16.16% -23.85% -18.01% -15.63%
Return on Common Equity (ROCE)		 -54.41% -52.92% -51.23% -119.78% -66.25% -49.08% -29.64% -29.25% -34.60% -21.14% -16.07%
Return on Equity Simple (ROE_SIMPLE)		 -50.91% 0.00% -42.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.50 -0.83 -0.64 -0.97 -0.76 -0.84 -0.53 -0.46 -0.44 -0.84 -0.78
NOPAT Margin		 -27.70% -38.57% -46.81% -105.31% -69.05% -73.83% -46.73% -44.50% -58.14% -68.53% -79.52%
Net Nonoperating Expense Percent (NNEP)		 6.70% 11.04% 7.69% 12.33% 11.92% 12.87% 8.09% 2.38% 6.69% 12.75% 11.46%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.93% -5.19% -8.55% -7.25% -7.41% -5.08% -4.62% -3.76% -3.21% -1.93%
Cost of Revenue to Revenue		 112.93% 103.49% 121.17% 209.78% 147.08% 114.31% 111.97% 108.68% 107.89% 87.56% 70.97%
SG&A Expenses to Revenue		 25.11% 44.16% 43.56% 21.98% 43.60% 91.18% 52.30% 52.85% 66.50% 96.90% 134.40%
R&D to Revenue		 2.54% 6.86% 2.30% 17.77% 7.96% 0.05% 2.60% -12.65% 5.33% 15.43% 8.52%
Operating Expenses to Revenue		 26.64% 51.61% 45.70% 40.67% 51.56% 91.16% 54.79% 40.20% 75.18% 110.26% 142.62%
Earnings before Interest and Taxes (EBIT)		 -0.71 -1.18 -0.92 -1.39 -1.09 -1.20 -0.76 -0.65 -0.63 -1.20 -1.12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.03 -0.49 -0.18 -0.65 -0.39 -0.69 -0.43 -0.33 -0.27 -0.63 -0.14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.28 0.53 0.29 0.53 0.62 0.58 0.73 0.00 0.00 0.27 0.08
Price to Tangible Book Value (P/TBV)		 0.38 0.95 0.65 1.31 1.87 4.25 12.67 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.22 0.57 0.38 0.63 0.73 0.99 1.18 0.00 0.00 1.47 0.77
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.50 0.67 0.49 0.67 0.75 0.69 0.81 0.00 0.00 0.35 0.16
Enterprise Value to Revenue (EV/Rev)		 0.57 1.01 0.88 1.15 1.31 1.63 1.89 0.00 0.00 2.21 1.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 3,862.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 30.94 21.96 0.00 0.00 77.21 0.00 0.00 61.67 37.74
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.68 0.61 0.49 0.54 0.61 0.46 0.50 0.53 0.41 0.15 0.09
Long-Term Debt to Equity		 0.23 0.19 0.17 0.19 0.22 0.18 0.20 0.20 0.00 0.00 0.00
Financial Leverage		 0.93 0.62 0.63 0.64 0.48 0.40 0.41 0.44 0.43 0.20 0.14
Leverage Ratio		 3.53 2.92 2.59 2.55 2.28 2.06 1.99 2.02 1.97 1.51 1.35
Compound Leverage Factor		 3.84 3.03 2.70 2.63 2.35 2.11 2.06 1.64 2.05 1.53 1.38
Debt to Total Capital		 40.44% 37.73% 32.91% 34.94% 37.70% 31.43% 33.34% 34.65% 28.84% 13.05% 8.40%
Short-Term Debt to Total Capital		 26.87% 25.93% 21.50% 22.62% 24.08% 19.12% 20.02% 21.30% 28.84% 13.05% 8.40%
Long-Term Debt to Total Capital		 13.57% 11.79% 11.40% 12.32% 13.62% 12.31% 13.32% 13.35% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 59.56% 62.27% 67.09% 65.06% 62.30% 68.57% 66.66% 65.35% 71.16% 86.95% 91.60%
Debt to EBITDA		 -106.13 2,463.93 -8.79 -2.94 -2.31 -1.86 -1.62 -1.81 -1.89 -2.06 -2.48
Net Debt to EBITDA		 -71.09 1,687.15 -6.98 -2.39 -1.89 -1.53 -1.42 -1.48 -1.74 -1.85 -2.36
Long-Term Debt to EBITDA		 -35.62 770.26 -3.05 -1.04 -0.83 -0.73 -0.65 -0.70 0.00 0.00 0.00
Debt to NOPAT		 -2.17 -2.34 -1.78 -1.35 -1.23 -1.11 -1.12 -1.33 -1.49 -1.51 -1.35
Net Debt to NOPAT		 -1.45 -1.61 -1.41 -1.10 -1.01 -0.91 -0.99 -1.08 -1.37 -1.35 -1.28
Long-Term Debt to NOPAT		 -0.73 -0.73 -0.62 -0.48 -0.45 -0.43 -0.45 -0.51 0.00 0.00 0.00
Altman Z-Score		 -3.10 -2.95 -3.13 -3.69 -4.04 -3.87 -4.06 0.00 0.00 -1.88 -1.41
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.82 0.88 0.89 0.84 0.79 0.65 0.56 0.51 0.35 0.32 0.28
Quick Ratio		 0.25 0.31 0.21 0.22 0.23 0.18 0.15 0.18 0.08 0.09 0.06
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.03 -2.88 -2.51 -2.98 -1.63 -0.96 0.93 0.93 -2.10 -16 -31
Operating Cash Flow to CapEx		 1,493.27% -493.11% 0.00% -258.94% 0.00% 1,528.64% -126.32% 0.00% -38,786.74% 33,477.97% 0.00%
Free Cash Flow to Firm to Interest Expense		 -15.62 -57.22 -59.65 -61.99 -47.76 -32.38 33.33 33.94 -87.13 -706.71 -1,190.47
Operating Cash Flow to Interest Expense		 15.21 -0.44 -13.88 -1.51 -1.38 10.05 -2.63 10.64 -9.86 6.72 -2.12
Operating Cash Flow Less CapEx to Interest Expense		 14.19 -0.53 -13.88 -2.09 -1.11 9.39 -4.71 10.64 -9.88 6.70 -2.12
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.49 0.41 0.38 0.42 0.38 0.29 0.28 0.31 0.28 0.18 0.13
Accounts Receivable Turnover		 17.50 12.60 12.26 19.21 14.27 9.79 11.32 14.64 12.17 14.99 12.76
Inventory Turnover		 2.39 2.18 1.93 2.34 2.38 2.17 2.17 2.36 2.17 2.20 2.13
Fixed Asset Turnover		 0.86 0.82 0.81 0.88 0.85 0.76 0.77 0.84 0.83 0.89 0.88
Accounts Payable Turnover		 3.10 2.31 2.48 3.57 3.04 2.30 2.24 2.29 1.81 1.46 1.21
Days Sales Outstanding (DSO)		 20.85 28.97 29.77 19.00 25.58 37.27 32.25 24.94 29.99 24.36 28.62
Days Inventory Outstanding (DIO)		 152.83 167.18 189.36 156.29 153.63 168.05 168.53 154.87 168.32 165.95 171.48
Days Payable Outstanding (DPO)		 117.77 157.82 147.26 102.15 119.97 158.48 162.75 159.20 201.28 250.25 302.14
Cash Conversion Cycle (CCC)		 55.92 38.33 71.88 73.14 59.24 46.83 38.02 20.60 -2.97 -59.94 -102.05
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 8.89 11 12 11 9.76 11 10 9.26 11 26 40
Invested Capital Turnover		 0.90 0.74 0.61 0.65 0.59 0.43 0.40 0.44 0.38 0.23 0.16
Increase / (Decrease) in Invested Capital		 0.54 2.05 1.87 2.01 0.87 0.13 -1.47 -1.39 1.66 15 30
Enterprise Value (EV)		 4.47 7.08 5.67 7.18 7.29 7.40 8.14 0.00 0.00 9.14 6.29
Market Capitalization		 1.69 3.99 2.45 3.94 4.06 4.48 5.07 0.00 0.00 6.08 3.06
Book Value per Share		 $0.53 $0.23 $0.25 $0.47 $0.38 $0.40 $0.36 $1.98 $2.15 $4.53 $7.37
Tangible Book Value per Share		 $0.39 $0.13 $0.11 $0.19 $0.13 $0.05 $0.02 $0.01 ($0.12) ($0.27) ($0.33)
Total Capital		 10 12 12 11 10 11 10 9.89 12 26 40
Total Debt		 4.15 4.52 4.07 3.98 3.95 3.55 3.49 3.43 3.37 3.41 3.39
Total Long-Term Debt		 1.39 1.41 1.41 1.40 1.43 1.39 1.39 1.32 0.00 0.00 0.00
Net Debt		 2.78 3.09 3.23 3.24 3.23 2.92 3.07 2.80 3.10 3.07 3.23
Capital Expenditures (CapEx)		 0.07 0.00 0.00 0.03 -0.01 0.02 0.06 -0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.14 0.86 1.22 1.10 0.78 -0.21 -0.59 -1.07 -1.19 -1.99 -2.04
Debt-free Net Working Capital (DFNWC)		 1.51 2.28 2.05 1.84 1.50 0.41 -0.18 -0.44 -0.92 -1.64 -1.87
Net Working Capital (NWC)		 -1.25 -0.82 -0.60 -0.74 -1.02 -1.75 -2.27 -2.55 -4.29 -5.05 -5.26
Net Nonoperating Expense (NNE)		 0.28 0.40 0.31 0.46 0.36 0.39 0.25 0.07 0.21 0.38 0.36
Net Nonoperating Obligations (NNO)		 2.78 3.09 3.22 3.24 3.23 2.92 3.07 2.80 3.10 3.07 3.23
Total Depreciation and Amortization (D&A)		 0.68 0.70 0.73 0.74 0.70 0.51 0.33 0.32 0.36 0.57 0.98
Debt-free, Cash-free Net Working Capital to Revenue		 1.75% 12.22% 18.92% 17.56% 14.13% -4.71% -13.74% -24.31% -29.41% -47.94% -51.05%
Debt-free Net Working Capital to Revenue		 19.35% 32.53% 31.99% 29.39% 27.09% 9.13% -4.13% -10.10% -22.81% -39.61% -46.83%
Net Working Capital to Revenue		 -16.07% -11.75% -9.40% -11.83% -18.42% -38.57% -52.87% -58.00% -105.95% -121.95% -131.88%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.30) ($1.80) ($0.70) ($0.90) ($0.60) ($7.00) ($0.24) ($0.16) ($0.17) ($0.28) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding		 2.64M 676.72K 1.31M 1.61M 1.73M 174.64K 3.26M 3.26M 3.87M 4.29M 25.60M
Adjusted Diluted Earnings per Share		 $0.00 ($1.80) $0.00 $0.00 ($0.60) ($7.00) ($0.24) ($0.16) ($0.17) ($0.28) ($0.04)
Adjusted Weighted Average Diluted Shares Outstanding		 6.59M 2.96M 1.59M 1.72M 1.93M 0.00 0.00 0.00 5.02M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.80) $0.00 $0.00 $0.00 ($7.00) $0.00 $0.00 $0.00 ($0.28) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.59M 2.96M 1.59M 1.72M 1.93M 0.00 0.00 0.00 5.02M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -0.50 -0.83 -0.64 -0.97 -0.76 -0.84 -0.53 -0.46 -0.44 -0.84 -0.78
Normalized NOPAT Margin		 -27.70% -38.57% -46.81% -105.31% -69.05% -73.83% -46.73% -44.50% -58.14% -68.53% -79.52%
Pre Tax Income Margin		 -43.12% -57.32% -69.78% -155.48% -101.61% -107.98% -69.14% -51.51% -86.15% -99.69% -116.23%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -10.77 -23.57 -21.73 -28.91 -31.81 -40.23 -27.07 -23.84 -26.12 -53.10 -42.92
NOPAT to Interest Expense		 -7.54 -16.50 -15.21 -20.23 -22.27 -28.16 -18.95 -16.69 -18.29 -37.17 -30.04
EBIT Less CapEx to Interest Expense		 -11.79 -23.66 -21.73 -29.49 -31.54 -40.89 -29.15 -23.83 -26.15 -53.12 -42.92
NOPAT Less CapEx to Interest Expense		 -8.56 -16.59 -15.21 -20.82 -22.00 -28.82 -21.03 -16.68 -18.31 -37.19 -30.04
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

China Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, China Pharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

China Pharma's net income appears to be on a downward trend, with a most recent value of -$3.19 million in 2025, falling from -$15.41 million in 2015. The previous period was -$4.74 million in 2024.

China Pharma's total operating income in 2025 was -$3.24 million, based on the following breakdown:
  • Total Gross Profit: -$131.95 thousand
  • Total Operating Expenses: $2.96 million

Over the last 10 years, China Pharma's total revenue changed from $20.35 million in 2015 to $4.14 million in 2025, a change of -79.6%.

China Pharma's total liabilities were at $8.26 million at the end of 2025, a 15.7% increase from 2024, and a 65.4% decrease since 2015.

In the past 10 years, China Pharma's cash and equivalents has ranged from $345.11 thousand in 2025 to $6.25 million in 2015, and is currently $345.11 thousand as of their latest financial filing in 2025.

Over the last 10 years, China Pharma's book value per share changed from 1.67 in 2015 to 4.53 in 2025, a change of 171.6%.


Related Companies

Financial statements for NYSE:CPHI last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel